Axinn Assisted Actavis in Resolving Ten-Year-Old Dispute with Pfizer
March 1, 2012
"Axinn assisted Actavis in resolving a ten-year-old dispute with Pfizer over its Neurontin (gabapentin) epilepsy drug during the jury trial of the case. Pfizer sued Purepac/Actavis, Teva and IVAX in 2000, claiming that their generic gabapentin products infringed a Pfizer patent on specific gabapentin formulations, and resulting in Pfizer losing $2 billion in the first year of generic competition. Actavis succeeded at trial in barring several of Pfizer's expert witness opinions on the patent infringement issue. The companies had completed two weeks of what was expected to be a six-week jury trial before the settlement was announced.
Axinn's Fran Morrison, who led the Actavis trial team, stated, "We are thrilled to be able to assist Actavis in resolving this case on favorable terms, and in avoiding a significant claim for damages. The outcome of the case reflects the hard work of the Actavis management and legal teams, and the Axinn trial team. We expect that Actavis will continue to prosper as it moves beyond this long-running dispute."
To subscribe to our publications, click here.
Featured Insights
Featured Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
Keeping an Eye on the Ball: America First Antitrust Weighs in on the “Uniquely American System of Scholar Athletics”
Axinn Viewpoints
Antitrust
Wait, We Have To Tell Who? What You Need To Know About State Premerger Notifications
Podcast
MBK | MSK Fellowship Summit 2025
Sponsorship
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Axinn Attorneys Recognized by IAM Patent 1000
News
Intellectual Property